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Introduction
Neuroinflammation and neuroregeneration processes coexist in multiple sclerosis (MS). Although the clinical course differs in each patient, it is not known what the causative factor is in a favorable or unfavorable clinical course. Apart from clinical data, biochemical-serologic, radiologic, electrophysiologic studies and biomarker identification studies have been conducted in order to identify factors and markers related to clinical course. A biomarker is simply an indicator that can be objectively measured and evaluated in response to a normal biologic or pathologic process or response after a treatment. It can be used for diagnosis, staging, and as a prognostic indicator of the disease, predicting treatment response or follow-up of treatment (1) . In this short review study, the aim was to compile biomarkers that reflect the progress and development of disability in MS that have been introduced in the past 5 years. The presence of biomarkers at the time of diagnosis will be of value in determining whether high-efficacy/high-risk treatment selection is required or whether monitoring at the time of treatment is effective/ineffective.
Which pathophysiologic processes are observed in MS and why do individual differences arise?
When the progression of MS is examined, it is observed, with the simplest approach, that there is a relapsing-remitting or progressive course. Tissue inflammation consisting predominantly of immune cells creates local areas of demyelination called plaques in brain regions in the course of the episodes, and a 'generalized inflammatory state,' which is a diffuse microglia activation in the entire brain, has been shown recently (2) . Immune activation has its own cell destruction effect as well as causing disruption in the mitochondrial genetic structure, thus leading to a decrease in mitochondrial function and energy production (3) . The trophic support cycle between neurons and glia is disturbed and the cell life cycle is diverted to apoptosis (4) . Besides the reduction in energy production, the contribution of vascular deficiency was identified in recent years in the area of inflammation (5) and the excessive energy consumption of channel structures reorganized during the remyelination process lead to an energy bottleneck. Energy deficiency can lead to increased intracellular calcium accumulation and triggering of apoptotic processes, formation of toxic substances such as reactive oxygen products, and inadequate purification processes (6) . Unlike the relapsing-remitting course, immune activation in the progressive course continues with microglia instead of T and B cells. After increased tissue damage, axonal degeneration becomes widespread with anterior-posterior extensions. Mechanisms that generate toxic responses are further activated by releasing iron accumulated in the tissue, the energy bottleneck increases, the regenerative ability decreases with advancing age, and consequently disability develops without episodes (7) . Although disability appears to be a result of anatomic destruction and physiologic insufficiency in the neural structure in the relapsing-remitting course, anatomic destruction seems to be associated with physiologic destruction in the progressive course.
The neuroinflammation/neurodegeneration processes in MS pathophysiology could be summarized as follows;
1. Deformation or structural changes occur in normal tissue structure.
2. After the structural change, the energy demand increases and the inefficient-excessive energy consumption develops.
3. The processes developed for adaptation become maladaptive. 4 . Cell death rate increases with insufficiency in the regeneration process or the amount of cell damage.
The presence of different prognosis-disability in patients with MS can be explained by the absence of therapeutic agents or differences in the efficacy of these agents, individual variability such as sex and age of onset, presence of toxic agents or other variables not yet defined along with this process.
What are the factors-biomarkers associated with disability?
Clinical, radiologic, and immunologic studies of the biomarkers will be grouped, but it should be remembered that these groups are intertwined (Tables 1, 2, 3). As negative factor and biomarker studies herald disability, they are more noticeable than positive factors and biomarker studies and their number is therefore greater (a summary of the studies is given in Table 4 ). High GFAP and chitinase-3-like-1 levels were associated with early EDSS 3 increase. Chitinase-3-like-1 was associated with early progression to EDSS 6.
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Clinical Biomarkers
Disability does not develop in some clinical and radiologic MS cases and these phenomena are known as 'benign MS'. Although benign MS contains different definitions, it is commonly defined as "Expanded Disability Status Scale (EDSS) values being below 2 or 3 within 10-15 years". In a study that questioned the characteristics of patients with benign MS, 307 patients were followed prospectively for 15 years and it was seen that patients with benign MS included those with complete remission of the onset attack, low or moderate initial relapse frequency, and dominating afferent symptoms (8) .
In another study, benign MS was defined as having EDSS values below 2 and 3 separately for 10-year disease duration and 19.8% to 33.3% among 6258 patients were characterized as having benign MS. Positive prognostic factors at baseline included female sex and younger age at onset, and disease-modifying treatment and longer disease duration were found to be positive predictors at the end of 4 th year (9) . In another study with long-term follow-up, the benign MS definitions of the previous study were used, female sex and the presence of fully recovering attacks with a low number of attacks indicated favorable outcome at the 20 th and 30 th years and 30 th year, respectively. In this study, the number of cases in the 10 th , 20 th , and 30 th year groups decreased by half every 10 years, and the benign characteristics of the patients disappeared (10) . This result shows that patients with benign MS with better outcomes have a long-term risk of developing disability.
A meta-analysis of placebo-controlled, randomized trials of disease-modifying treatments in patients with relapsing MS has shown that disease-modifying treatment reduces the frequency and severity of relapses and slows down disability, independently of the route of administration and their classification as first or second-line therapies (11) . It was questioned in a study whether there was any difference in clinical course and disability development before and after the disease-modifying treatment period. The time to reach an EDSS value of 6 during the period between 1980 and 2013 was examined with 5-year intervals, and it was shown that the course had changed after 2000 and the time to EDSS increase had extended. For example, the proportion of patients who reached EDSS 6 at the age of 50 years before 2000 was 27%, whereas it was significantly lower (15%) after 2000. Decreased age of diagnosis due to changing disease definitions, shortening of the delay period in taking the treatment, and the emergence of more effective treatments were emphasized among the reasons for this change, and treatment has been shown to postpone the increase in EDSS (12) . The effect of time to initiate treatment on disability was questioned in relapsing MS and it was shown that the initiation of treatment before 3 years from MS onset had a significant decreasing effect on disability (13) . The study was conducted with 639 patients for 8 years, and development of early disability and late age at onset were other prognostic factors. In another study in which 512 patients receiving disease-modifying treatment were followed for 17 years, both the duration of disability development and the time of secondary progression were found to be longer than those of natural history studies, which was attributed to the treatment affect (14) . During the 17-year follow-up period, 36-50% of the cases were expected to have secondary progressive MS (SPMS), but only 11.3% had progressed to SPMS.
When the role of paroxysmal symptoms (lasting seconds to minutes and occurring many times a day) and unusual cortical findings (aphasia or epileptic seizures) as initial manifestations of MS was examined in a cohort of 512 patients with relapsing onset MS who were followed up for a mean period of 12 years, it was shown to be similar to classic symptoms and findings in terms of conversion rates to MS and causing disability, thus not being benign as it is supposed to be (15) .
In a study investigating clinical prognostic factors affecting EDSS elevation, it was found that male sex, being of African descent, non-recovery after the first relapse, two or more relapses during the first year, a short interval between initial relapses, initial polysymptomatic presentation of pyramidal and cerebellar dysfunction and no treatment prior to reaching EDSS 3 were factors associated with EDSS increase (16) . The incidence of MS is low among those with African ancestry, but the EDSS increase is early and the clinical course is worse (17) .
The age of onset of illness is an important variable in disability worsening. When the relationship between MS disease type, patient age, and disability was examined, it was revealed that disability in progressive MS [SPMS, primary progressive MS (PPMS)] was related to age independently of previous disease activity or disease duration (18) . The EDSS increase in patients with an onset age of 50 years or less was shorter than that in those aged less than 50 years, independent of disease course (19) . In addition to the age variable, MS duration, baseline brain volume, EDSS score, and T2 disease burden were investigated in another study; higher baseline brain volume and receiving treatment predicted better long-term clinical outcomes, and higher baseline and greater early increase in EDSS score predicted worse outcomes (20) . When the importance of the age of onset, cortical lesion volume, and cerebellar cortical volume variables in patients with relapsingremitting MS (RRMS) were questioned at the time of entry into the study, the model correctly identified 94% of patients who maintained the relapsing-remitting course and 88% patients who became secondary progressive at the end of 5 years (21) . The period of transition to a secondary progressive course was observed to be shortened in the presence of male sex, onset after the age of 30 years, and 3 or more relapses in the early period. It was observed that patients reaching EDSS 8 from onset of progression had 3 or more relapses, and had cerebellar and brainstem symptoms during relapses (22) . The effect of smoking on the development of secondary progression was investigated with the age of onset of progression, and reaching SP disease was found to be at 48 years in patients who continued to smoke and 56 years of age in patients who quit smoking. Therefore, it was concluded that smoking worsens the course of the disease (23) .
Relapse frequency is an indication of disease activity and also a risk factor for an increase in disability. It is one of the treatment targets. In addition to the frequency of relapses, the domain affected by the relapse is also important in the increase in disability. It has been shown that relapses in pyramidal, cerebellar, and bowel/ bladder systems lead to higher EDSS increases compared with relapses with brainstem, visual, sensory, and cerebral involvement (24) . In pediatric MS, the use of disease-modifying treatment and age of onset under the age of 15 years were factors that decreased the risk of EDSS increase, and relapses increased the risk. It has been reported that relapses with multifocal or isolated spinal cord or optic nerve involvement during follow-up had a higher incidence of EDSS-worsening compared with relapses with isolated supratentorial or brainstem syndrome (25) .
Cognitive impairment is a condition observed during the course of MS. There is a relationship between age and cognitive impairment, as well as a relationship between long duration of illness and high EDSS values and cognitive impairment. This relationship also occurs independently of disease subtypes. Cognitive impairment was observed in 35% of patients with clinical isolated syndrome (CIS), 45% of patients with RRMS, 80% of patients with SPMS, and 91% of patients with PPMS (26) . In a meta-analysis study, there were differences in the subfunctions of cognitive impairment observed in patients with RRMS and PPMS. In patients with SPMS, processing speed, and verbal learning and memory were shown to be worse than in those with RRMS. Patients with RRMS had more deterioration in working memory, cognitive fluency, and higher executive functions, and it was emphasized that both groups needed more specialized disease management (27) .
When the importance of cognitive status at the onset of disease was investigated in a retrospective series of 78 patients for 8 years, early cognitive impairment was predictive of conversion to definite MS, disability increase, transition to the secondary progressive phase, and cortical thinning (28) . Despite a decrease in the frequency of relapses, no difference in progression in the meta-analysis of patients with SPMS treated with interferonbeta (IFN-β) was interpreted as that the anti-inflammatory effect of IFN-β was unable to prevent MS progression (29) . In a study with natalizumab, inflammatory activity was defined by the Rio score. According to the Rio score, ≤4 new T2 lesions on magnetic resonance imaging (MRI) was scored as 0 points, >4 new T2 lesions on MRI as 1 point, no relapses as 0 points, 1 relapse as 1 point, and ≥2 relapses as 2 points. This scoring was predictive of short-term (1-2 years) EDSS progression, but did not predict longer term (3-7 years) EDSS progression (30) . In patients treated with natalizumab, those receiving treatment aged over 50 years were found to be less responsive to treatment patients aged under 50 years (31) .
In patients with MS, disease-modifying treatment may be interrupted or discontinued. It can be discontinued due to compulsory reasons such as treatment adverse effects, pregnancy, as well as due to personal preferences such as planning to have a baby, or stable disease course. Patients who discontinued glatiramer acetate and IFN therapy due to similar reasons were retrospectively investigated, and age >45 years at discontinuation, absence of relapses for ≥4 years, and absence of contrast enhancing lesions were found to be independent predictors of absence of relapse after discontinuation. It has also been shown that demographic and clinical data can be predicted well without MRI data. The predictors of EDSS increase after discontinuation of therapy were high EDSS scores, age over 45 years, and long disease duration (32) .
The relationship between somatosensory evoked potentials (SEP) and motor evoked potentials (MEP) scores, which are evoked potential examinations, and EDSS values was examined in a crosssectional study, and found to be related (33) . SEP and MEP scores explained 58% of EDSS variability. Consecutive studies have shown that the relationship between EDSS scores and evoked potentials persisted at ten years and up to 15 years after disease onset. This suggests that the EDSS increase may be predicted by the early stage increased evoked potential scores (34) . MEP and visual evoked potential data together with age and treatment status were able to predict 58% of EDSS variability at 20 years (35) . Neither baseline EDSS nor T2-lesion or gadolinium-enhancing lesion quantities improved the prediction of EDSS.
The relationship between retinal nerve fiber layer thickness measurement by optical coherence tomography and EDSS was evaluated in a 5-year retrospective study, and thickness less than or equal to 87 μm or less than or equal to 88 μm was shown to have a risk of increased EDSS in patients with all other disease variables under control (36) .
Radiologic Biomarkers
In a review study examining the effectiveness of first-line treatment, it was investigated whether early-onset MRI parameters could predict clinical response and EDSS increase between 2-5. years. New or enlarging T2-weighted lesions ≥1, new or enlarging T2-weighted lesions ≥2, and Rio score ≥2 were used as criteria. As a result, it was observed that all criteria had a limited predictive value and that more sensitive measures of treatment failure at short term were needed (37) .
Upper cervical cord area on MRI has been as reduced in CIS and RRMS, and negatively correlated with muscular weakness and fatigability. The atrophy change rate was higher in the upper cervical cord area compared with white matter and gray matter, and this might have potential value (38) . It has been shown that spinal cord lesion number, change in cord lesion number in 5 years, and change in upper cervical cord area in patients with CIS with no spinal involvement were associated with EDSS, and that asymptomatic spinal cord lesions contribute to the development of disability over the first 5 years (39) . Regarding the absence of lesions, the presence of at least 1 lesion in the spinal cord was predictive of reaching EDSS 4 (40) .
Involvement of cerebellar gray matter is associated with disability scores, independent of cerebral gray matter involvement. Disability scores are EDSS, cerebellar functional system score, and arm and leg functions. In addition, patients with a high burden of cerebellar leukocortical lesions had lower paced auditory serial addition test (PASAT) scores, whereas patients with greater volumes of cerebellar intracortical lesions had worse symbol digit modalities test scores (41) . In a study aimed at detecting variables for prediction of disability outcomes using clinical and MRI parameters, T2 lesion number, T1 and T2 lesion volumes, corpus callosum, and thalamic fraction were the best predictors at baseline, and EDSS and its change, corpus callosum volume change and number of new or enlarging T2 lesions at 12 months were the best predictors. Based on 12-year follow-up data, a composite score was generated from a subset of the best predictors and it was shown that scores of ≥4 had greater specificity for predicting worsening compared with the individual predictors (42) .
In a retrospective study, the relationship between baseline and first 2-years MRI imaging and EDSS scoring after 10 years was investigated, and it was seen that EDSS at 10 years could be predicted by whole brain and central atrophy, and T2-weighted lesion volume change (43) .
In another study, MRI-based brain volume measurements were used to calculate observed and expected normalized brain volume based on age, sex, T2-lesion volume, and baseline EDSS. Low, normal, and high values were calculated, and the difference between observed and expected values was found; there was a relationship between baseline brain volume and 2-4-years disability development (44) . The brain volume loss rate in the first 2 years was similarly related to 2-4-years disability development (45) . However, more time is needed for using in clinical practice, because brain volume measurements have not yet entered routine practice and the method requires experience. When patients with RRMS in randomized controlled trials were examined by metaanalysis, it was found that the treatment effect on disability progression was independently correlated with brain atrophy and the presence of active MRI lesions (46) .
In a group of 42 patients with MRI volume measurement and with a mean follow-up of 30 months, baseline thalamus, caudate, and putamen volumes predicted subsequent 25-ft walk test and MSFC, and as well as loss of volume in these structures (47) . A broad review of MRI parameters has also been published recently (48) .
Baseline cortical N-acetyl aspartate/creatine (NAA/Cr) and EDSS at month 24 and at the 7-year follow-up were correlated, whereas patients with EDSS ≥4 had a lower baseline cortical NAA/ Cr (49) .
In a study investigating black holes using 11C-PK11195 positron emission tomography, which shows microglial activity in progressive subjects, black holes were found not to be inactive, but surrounded by activated microglia and associated with disability (50) .
Another method of study associated with MRI is to examine the default mode network with functional MRI. In one study, the network connections of the hippocampus region with other cortical-subcortical structures were questioned and reduced hippocampal-resting state functional connectivity was found to be associated with higher T2 lesion volume, longer disease duration, and the severity of depression and disability (51) .
Immunologic Biomarkers
Human leukocyte antigen (HLA) is divided into major histocompatibility complex (MHC) class 1 (HLA A, B, C) and MHC class 2 (HLA-DR-DQ). In a study investigating the relationship between HLA genotype and MS prognosis, it was reported that HLA-A2 favored a better prognosis, HLA-B7 and B44 favored a poor prognosis, and HLA-DRB115, HLA-DQB16 and HLA-B8 alleles were inconclusive (52) . In another study, HLA-DRB1*01 and DRB1*04 alleles were found to be associated with a worse prognosis when considering the time to reach an EDSS 6 (53) . It was investigated whether variations in the myelin basic protein gene altered clinical course (conversion to MS and change in disability) in 127 persons who had had a first demyelinating event and followed up to the 5-years review, and rs12959006 was found to be associated with worse clinical outcomes. It was decisive for relapse and disability progression (54) . In a study aimed at identifying loci bearing genetic risk associated with MS, there was a linear relationship between the upper cervical cord area, which is an MRI parameter, and 9 loci and an inverse relationship with 3 loci (55).
Conversion to MS in CIS can be interpreted as a poor prognostic criterion. Cerebrospinal fluid (CSF)-soluble CD27, a T cell activation marker, predicted the conversion to MS in patients with CIS and was also associated with a high relapse rate (56) . In a study with a 14-year follow-up period, it was observed that, together with MRI parameters, chitinase-3-like-1 and age predicted conversion to MS. Chitinase-3-like-1 predicted longterm cognitive impairment 1 the PASAT test, and neurofilament light-chain (NfL) predicted long-term disability in the MS severity scale and nine-hole-Peg-test (57) . In a study involving 813 patients with CIS, it was shown that CSF chitinase-3-like-1 was an independent risk factor for conversion to MS and reaching EDSS 3 (58) . High CSF chitinase-3-like-1 was also associated with early conversion to MS and early development of disability. In a study involving patients with CIS and RRMS with a mean followup time of 11 years, glial fibrillary acidic protein and chitinase-3like-1 were associated with conversion to MS and progression to EDSS 3, and chitinase-3-like-1 was associated with progression to EDSS 6 (59) .
Vitamin D and MRI variables were examined during IFN treatment, and a 50 nmol/L (20 ng/mL) increment in average serum vitamin D levels within the first 12 months predicted a lower relapse rate (57%), lower rate of new active lesions on MRI (57%), lower yearly increase in T2 lesion volume (25%), lower yearly loss in brain volume (41%), and less disability (60) .
In a cross-sectional study, there was a correlation between higher serum levels of interleukin (IL)-33, a member of the inflammatory IL family, IL-37, a member of the anti-inflammatory IL family, and a soluble form of vascular endothelial growth factor receptor 2 with disease severity according to EDSS (61). However, these parameters, which are high in other diseases with immunopathogenesis, are not specific for MS, thus drawing attention to the necessity of repeating the results and long-term follow-up. The relationship between serum energy metabolism biomarkers and disability, disease course, and MRI was examined, and serum lactate, creatinine, purines (hypoxanthine, xanthine, uric acid, inosine) and pyrimidines (uracil, beta-pseudouridine, uridine) were scored. Although there were different scores among patients with RRMS and progressive MS, there was a relationship with EDSS and MRI parameters (62) .
CSF β-amyloid levels were reduced in patients compared with controls, lower CSF β-amyloid levels at baseline were a disability predictor at 3-year follow-up and CSF tau levels correlated with T2-and T1-lesion load on MRI (63) . When CSF NfL at baseline in NEDA + (patients who showed no evidence of disease activity) and EDA + (patients who showed evidence of disease activity) patients with CIS and RRMS were compared with normal subjects, NEDA + patients were found to be similar to the normal group, and EDA + patients were different. NfL values predicted disease activity alone with 85% accuracy during 2 years of followup (64) . CSF neurofilament heavy-chain (NfH) values were found to correlate with EDSS in a 17-year follow-up period, to reflect chronic axonal destruction (65) , and also to estimate the amount of brain and spinal cord atrophy on MRI (66) . Although it is stated that there is a relationship between CSF-serum values and that they can be used interchangeably, it should be remembered that NfH is not specific to MS (67) . The occurrence of CSF oligoclonal bands (OCB) was found associated with an increase in gray matter lesions, high NfH ratio, and increased levels of pro-inflammatory mediators and several inflammatory mediators linked to B lymphocyte activity over a 10-year follow-up. It has also been shown that the occurrence of OCB was associated with physical and cognitive impairment (68) , and that OCB-patients had a better prognosis and milder disability than OCB+ patients (69) . However, the prognostic value of OCB remains unclear because some other studies have not shown a relationship (70) . In a study investigating the value of the immunoglobulin (Ig) M index in patients with RRMS and SPMS, IgM index values, unlike IgG index, were correlated with EDSS and MRI parameters, and were higher in patients with SPMS (71) .
Neutralizing antibodies observed during biologic agent treatment can also be a countervailing factor in reducing treatment efficacy. Fourteen percent of patients had neutralizing antibody during IFN-β-1a/1b treatment; neutralizing antibodies lead to an increase of the relapse rate, decreased time to 1 st relapse, and a negative trend in the time to reach the EDSS 4 milestone (72) .
Conclusion
In addition to current treatments aimed at reducing the frequency and severity of relapses, as well as disability development, it is hoped that treatments providing regeneration and disabilityfree course will be added to clinical use. The most utopian point is preventive treatment, which can prevent disease formation before it starts. Until these goals are achieved, there is a need to recognize and use disease-related prognosis-disability biomarkers to demonstrate correct behavior at the right time.
In this study, the data obtained in the last 5 years were searched from the PubMed database using the keywords "multiple sclerosis", "disability", "prognosis OR prognostic" and "predictive OR prediction" and 1068 publications were found between 2012-2017. Of these, 295 were reached in full text and 33 different publications were also reviewed. Although the study reflects the recent data, it has limitations due to reasons such as the fact that data from previous years have been partially evaluated and only one database was scanned in the English language.
Ethics Peer-review: Externally and internally peer-reviewed. Financial Disclosure: The author declared that this study received no financial support.
